Research Article

The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer

Volume: 54 Number: 2 August 26, 2024
EN

The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer

Abstract

Background and Aims: :Poor prognosis in lung cancer is associated with tumor-associated macrophages (TAMs) that exhibit M2clike behaviours that support multiple pathways in the tumour microenvironment. The interplay between epigenetic modifications and the ubiquitin-proteasome pathway involves three key mechanisms: regulation of epigenetic enzymes by ubiquitin, interaction between ubiquitin and epigenetic modifiers, and epigenetic silencing of critical genes involved in cellular processes. Therefore, we investigated the effects of ixazomib, a proteasome inhibitor, on gene expression changes in epigenetic chromatin modification enzymes in a co-culture of M2c macrophages and A549 lung cancer cells. Methods: The IC50 concentration of ixazomib was determined to be 2.19 μM using a real-time cell analyser. THP-1 monocytes were polarised into M0 macrophages with 100 ng/mL phorbol 12-myristate 13-acetate (PMA), rested, and then exposed to 1 mM hydrocortisone to becomeM2cmacrophages.A549cellswereseededinthelowerchamberofaco-cultureplate.M2cmacrophages were then co-cultured with A549 cells for 24 h with or without 2.19 μM ixazomib. After being isolated, mRNA was converted to cDNAand analysed using a gene panel with RT-PCR. Results: The findings showed that 56 genes had exceptionally high expression levels (up to 1848-fold. Ixazomib downregulated these overexpressed genes. Conclusion: Ixazomib effectively modulates the expression of genes involved in epigenetic chromatin modification in the lung cancer microenvironment, indicating its utility in lung cancer therapy. Further studies are needed to explore the combined use of epigenetic drugs and proteasome inhibitors.

Keywords

Supporting Institution

Anadolu University

Project Number

2103S115

Thanks

This research was supported by Anadolu University Scientific Research Project Commission (Project number: 2103S115).

References

  1. Atri, C., Guerfali, F.Z., & Laouini, D. (2018). Role of human macrophage polarization in inflammation during infectious dis-eases. International Journal of Molecular Sciences, 19(6), 1801. google scholar
  2. Baardman, J., Licht, I., De Winther, M.P.J., & Van den Bossche, J. (2015). Metabolic-epigenetic crosstalk in macrophage activation. Epigenomics, 7(7), 1155-64. google scholar
  3. Bestor, T.H. (1992). Activation of mammalian DNA methyltransferase by cleavage of a Zn binding regulatory domain. The EMBO Jour-nal, 11(7), 2611-7. google scholar
  4. Bruinsma, C. F., Savelberg, S. M., Kool, M. J., Jolfaei, M. A., Van Woerden, G. M., Baarends, W. M., & Elgersma, Y. (2016). An essential role for UBE2A/HR6A in learning and memory and mGLUR-dependent long-term depression. Human molecular ge-netics, 25(1), 1-8. google scholar
  5. Chanput, W., Mes, J. J., & Wichers, H. J. (2014). THP-1 cell line: an in vitro cell model for immune modulation approach. International immunopharmacology, 23(1), 37-45. google scholar
  6. Damaskos, C., Tomos, I., Garmpis, N., Karakatsani, A., Dimitroulis, D., Garmpi, A., ... & Tomos, P. (2018). Histone deacetylase in-hibitors as a novel targeted therapy against non-small cell lung cancer: where are we now and what should we expect?. Anti-cancer Research, 38(1), 37-43. google scholar
  7. Dikmen, M., Canturk, Z., Tilki, E. K., & Engur, S. (2017). Evalua-tion of antiangiogenic and antimetastatic Effects of Penicillium chrysogenum Secondary Metabolites. Indian J Pharm Sci, 79(1), 49-57. google scholar
  8. Dikmen, M., Öztürk, S. E., Cantürk, Z., Ceylan, G., Karaduman, A. B., & Yamaç, M. (2020). Anticancer and antimetastatic activity of Hypomyces chrysospermus, a cosmopolitan parasite in different human cancer cells. Molecular Biology Reports, 47, 3765-3778. google scholar

Details

Primary Language

English

Subjects

Basic Pharmacology

Journal Section

Research Article

Publication Date

August 26, 2024

Submission Date

August 2, 2023

Acceptance Date

June 29, 2024

Published in Issue

Year 2024 Volume: 54 Number: 2

APA
Kaya Tilki, E., & Engür Öztürk, S. (2024). The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer. İstanbul Journal of Pharmacy, 54(2), 215-222. https://doi.org/10.26650/IstanbulJPharm.2024.1336667
AMA
1.Kaya Tilki E, Engür Öztürk S. The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer. iujp. 2024;54(2):215-222. doi:10.26650/IstanbulJPharm.2024.1336667
Chicago
Kaya Tilki, Elif, and Selin Engür Öztürk. 2024. “The Proteasome Inhibitor Ixazomib Targets Epigenetic Chromatin Modification Enzymes Upregulated by M2c Macrophage Polarisation in Lung Cancer”. İstanbul Journal of Pharmacy 54 (2): 215-22. https://doi.org/10.26650/IstanbulJPharm.2024.1336667.
EndNote
Kaya Tilki E, Engür Öztürk S (August 1, 2024) The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer. İstanbul Journal of Pharmacy 54 2 215–222.
IEEE
[1]E. Kaya Tilki and S. Engür Öztürk, “The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer”, iujp, vol. 54, no. 2, pp. 215–222, Aug. 2024, doi: 10.26650/IstanbulJPharm.2024.1336667.
ISNAD
Kaya Tilki, Elif - Engür Öztürk, Selin. “The Proteasome Inhibitor Ixazomib Targets Epigenetic Chromatin Modification Enzymes Upregulated by M2c Macrophage Polarisation in Lung Cancer”. İstanbul Journal of Pharmacy 54/2 (August 1, 2024): 215-222. https://doi.org/10.26650/IstanbulJPharm.2024.1336667.
JAMA
1.Kaya Tilki E, Engür Öztürk S. The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer. iujp. 2024;54:215–222.
MLA
Kaya Tilki, Elif, and Selin Engür Öztürk. “The Proteasome Inhibitor Ixazomib Targets Epigenetic Chromatin Modification Enzymes Upregulated by M2c Macrophage Polarisation in Lung Cancer”. İstanbul Journal of Pharmacy, vol. 54, no. 2, Aug. 2024, pp. 215-22, doi:10.26650/IstanbulJPharm.2024.1336667.
Vancouver
1.Elif Kaya Tilki, Selin Engür Öztürk. The proteasome inhibitor ixazomib targets epigenetic chromatin modification enzymes upregulated by m2c macrophage polarisation in lung cancer. iujp. 2024 Aug. 1;54(2):215-22. doi:10.26650/IstanbulJPharm.2024.1336667